|1.||Mordente, Alvaro: 3 articles (11/2015 - 11/2006)|
|2.||Silvestrini, Andrea: 2 articles (11/2015 - 11/2006)|
|3.||Meucci, Elisabetta: 2 articles (11/2015 - 11/2006)|
|4.||Giardina, Bruno: 2 articles (10/2012 - 11/2006)|
|5.||Tavian, Daniela: 1 article (11/2015)|
|6.||Martorana, Giuseppe Ettore: 1 article (11/2015)|
|7.||Xu, Jinhui: 1 article (12/2014)|
|8.||Sheng, Yuan: 1 article (12/2014)|
|9.||Yu, Ying: 1 article (12/2014)|
|10.||Xu, Feifei: 1 article (12/2014)|
01/01/1986 - "In DX-treated mice traces of doxorubicinol (1%-3% of total fluorescence) were found in tumor and organs, and two aglycones were detected only at early times in the liver. "
07/01/2012 - "Because reduced conversion to doxorubicinol increases circulating levels of the more effective parent drug doxorubicin, it was hypothesized that therapeutic efficacy against tumors might also be enhanced. "
06/01/2007 - "This exploratory study suggests that the c.146A>G variation could contribute to the variations in the pharmacokinetics of doxorubicin and doxorubicinol in Asian cancer patients. "
07/01/2008 - "Plasma concentrations of doxorubicin and doxorubicinol were analyzed 20, 40, 60, and 120 minutes and 2 days after TACE, and liver tissue and tumor doxorubicin concentrations were measured 2 days after TACE. "
09/15/2000 - "Doxorubicinol (dxol) is the major metabolite formed in the hearts of cancer patients being treated with the widely used chemotherapeutic agent, doxorubicin (dox). "
|2.||Breast Neoplasms (Breast Cancer)
12/01/2014 - "Using this immunoisolation assay together with liquid chromatography-tandem mass spectrometry (LC/MS/MS), the subcellular distribution profiles of DOX and its main metabolite doxorubicinol (DOXol) in human breast cancer cells MCF-7/WT and MCF-7/ADR were determined and compared after the treatment of DOX and DOX-TRF. "
07/01/2008 - "Another variant CBR3 730G>A was associated with higher doxorubicinol AUC (P=0.009, GG vs. AA) and CBR3 expression in breast tumor tissue (P=0.001, GG vs AA). "
06/01/2007 - "To identify novel polymorphisms in the solute carrier SLC22A16 gene and determine their influence on the pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients. "
06/01/2007 - "Pharmacokinetic parameters of doxorubicin and doxorubicinol were estimated in Asian breast cancer patients undergoing adjuvant chemotherapy to investigate genotype-phenotype correlations. "
07/01/2008 - "A common CBR3 11G>A variant was associated with lower doxorubicinol area under the concentration-time curve (AUC)/doxorubicin AUC metabolite ratio (P=0.009, GG vs. AA; trend test, P=0.004), lower CBR3 expression in breast tumor tissue (P=0.001, GG vs. AA), greater tumor reduction (P=0.015, GG vs. AA), and greater percentage reduction of leukocyte and platelet counts at nadir (trend test, P < or = 0.03). "
|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
09/01/2008 - "Doxorubicinol, however, has also been considered responsible for the cardiomyopathy observed upon doxorubicin chemotherapy. "
11/01/2006 - "Secondary alcohol metabolites like doxorubicinol (DOXol) and daunorubicinol (DNRol), formed by cytoplasmic two-electron reductases, have been implicated as potential mediators of anthracycline-induced cardiomyopathy. "
11/01/2015 - "The development of anthracycline-induced cardiomyopathy has been found to correlate with myocardial formation and accumulation of anthracycline secondary alcohol metabolites (e.g., doxorubicinol and daunorubicinol) that are produced by distinct cytosolic NADPH-dependent reductases. "
10/01/2012 - "The anthracycline anticancer agents daunorubicin (DAUN) and doxorubicin (DOX) are reduced by different NADPH-dependent cytosolic reductases into their corresponding alcohol metabolites daunorubicinol (DAUNol) and doxorubicinol (DOXol), which have been implicated in the development of chronic cardiomyopathy. "
|5.||Body Weight (Weight, Body)
10/01/1995 - "In group 1 (n = 7) four single doses of DOX were injected in intervals of 15 minutes, in group 2 (n = 6) DOX was administered continuously during the first 30 min. The total dose in both groups was 1 mg/kg body weight, and the perfusion lasted 60 min. Concentrations of DOX and its major metabolite doxorubicinol (DOXol) were measured in perfusate and muscle tissue by high performance liquid chromatography (HPLC). "
07/01/1987 - "In a similar way, doxorubicinol treatment was associated with a significant inhibition of rat body weight increase, and the appearance of ECG alterations as well as both macro- and microscopic signs of cardiac tissue damage. "
01/01/1979 - "The model assumes an initial volume of distribution of 60% of body weight and includes two peripheral adriamycin compartments and a subsystem for adriamycinol, a major metabolite. "
09/01/1986 - "Adriamycinol inhibited rat body weight increase and induced the appearance of ECG alterations (especially S alpha T widening) as well as moderate histological cardiac lesions, but to a lesser extent and severity compared with adriamycin, which, in turn, markedly affected rat body growth, ECG parameters (especially the S alpha T segment and the T-wave) and the histological cardiac picture. "
|7.||DNA (Deoxyribonucleic Acid)
|5.||Drug Therapy (Chemotherapy)